Danaher (DHR) UBS Global Healthcare Conference summary

Strategic priorities and capital allocation

• Aim to lead in life sciences and diagnostics through faster, sustainable, profitable core growth and share gains; priorities include commercial execution, innovation, talent and capital allocation.

• DBS commercial excellence and cross-operating-company selling created hundreds of millions of dollars in incremental opportunity in diagnostics.

• M&A remains the capital-allocation priority; seek strategically compounding deals across biotechnology, life sciences and diagnostics, while staying disciplined when returns or strategic fit are lacking.

• At Masimo, an initial kaizen lifted productivity by over 50% in one process using 50% fewer resources.

Growth outlook and secular drivers

• Core growth is at mid-single digits excluding respiratory; secular tailwinds include biologics, AI drug discovery and a potential blood-based Alzheimer's biomarker market of up to $5B in 10 years.

• AI and autonomous science could create share gains; offerings span instruments, automation, software and consumables, with an autonomous lab and partnerships with Anthropic and NVIDIA.

• Reshoring represents a $1B incremental market opportunity, mainly in bioprocessing equipment; brownfield orders are appearing, with revenue impact expected in 2028 and beyond.

Biotechnology and Cytiva

• Cytiva is viewed as a long-term high-single-digit growth business, supported by biologics, biosimilars, reshoring and advanced modalities; its broad bioprocessing portfolio is positioned across workflows.

• No share loss is evident: commercial therapeutics remain specced in, new opportunities are being won at a rate consistent with share, and cell culture media and resin remain strong areas.

• Q3 equipment orders grew mid-teens; rising orders and backlog support 2027, with a typical 9-12-month order-to-revenue conversion timeline.

• About 100 originator products are coming off patent; incumbency supports Cytiva, which is specced into about 90% of monoclonal antibody volume.